Vascular Damaging Agents

Clinical Oncology

Volumn 19, Issue 6, 2007, Pages 443-456

  Patterson, D M ^a   Rustin, G J S ^a  

^a MOUNT VERNON CANCER CENTRE   (United Kingdom)

Author keywords

Angiogenesis inhibitors; chemotherapy; combretastatin; radiobiology; radiotherapy; vascular disrupting agents

Indexed keywords

5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; ANGIOGENESIS INHIBITOR; ANGIOSTATIN; ARSENIC TRIOXIDE; AURISTATIN PE; AXITINIB; BEVACIZUMAB; BIBF 1120; CARBOPLATIN; COMBRETASTATIN A1 PHOSPHATE; COMBRETASTATIN A4 PHOSPHATE; ENDOSTATIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GLYCERYL TRINITRATE; N [2 [(4 HYDROXYPHENYL)AMINO] 3 PYRIDINYL] 4 METHOXYBENZENESULFONAMIDE; N ACETYLCOLCHINOL PHOSPHATE; NPI 2358; PACLITAXEL; PIPERAZINEDIONE; PROTEIN TYROSINE KINASE INHIBITOR; SERINE 2 METHOXY 5 [2 (3,4,5 TRIMETHOXYPHENYL)VINYL]ANILIDE; SORAFENIB; STEROID; SUNITINIB; THALIDOMIDE; THROMBOSPONDIN 1; UNCLASSIFIED DRUG; VANDETANIB; VASCULAR TARGETING AGENT; VATALANIB;

ALOPECIA; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ATAXIA; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER PAIN; CANCER RADIOTHERAPY; CELL HYPOXIA; CELL POPULATION; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTINUOUS INFUSION; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; DRUG TARGETING; ENDOTHELIUM CELL; FATIGUE; GENE FUNCTION; HUMAN; HYPERTENSION; HYPOTENSION; ILEUS; KIDNEY CANCER; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MALAISE; MALIGNANT NEOPLASTIC DISEASE; MICROENVIRONMENT; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROLOGIC DISEASE; NEUROPATHY; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; RADIOBIOLOGY; SINGLE DRUG DOSE; TACHYCARDIA; TARGET ORGAN; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT OUTCOME; TREMOR; TUMOR VASCULARIZATION; URINE INCONTINENCE; VASCULAR ENDOTHELIUM; VISUAL DISORDER;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL PROLIFERATION; ENDOTHELIUM, VASCULAR; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RADIATION TOLERANCE; RADIOBIOLOGY; RADIOTHERAPY;

EID: 34347231300     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2007.03.014     Document Type: Article

References (198)

1. Siemann D.W., Bibby M.C., Dark G.G., et al. Differentiation and definition of vascular-targeted therapies. Clin Cancer Res 11 (2005) 416-420
2. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 6 (2000) 389-395
3. Fox S.B., Gasparini G., and Harris A.L. Angiogenesis: pathological, prognostic, and growth-factor pathways and their link to trial design and anticancer drugs. Lancet Oncol 2 (2001) 278-289
4. Carmeliet P. Angiogenesis in health and disease. Nat Med 9 (2003) 653-660
5. Folkman J. Tumour angiogenesis: therapeutic implications. N Engl J Med 285 (1971) 1182-1186
6. Folkman J., Merler E., Abernathy C., and Williams G. Isolation of a tumor factor responsible for angiogenesis. J Exp Med 133 (1971) 275-288
7. Senger D.R., Galli S.J., Dvorak A.M., Perruzzi C.A., Harvey V.S., and Dvorak H.F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219 (1983) 983-985
8. Leung D.W., Cachianes G., Kuang W.J., Goeddel D.V., and Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246 (1989) 1306-1309
9. Plouet J., Schilling J., and Gospodarowicz D. Isolation and characterization of a newly identified endothelial cell mitogen produced by AtT-20 cells. EMBO J 8 (1989) 3801-3806
10. Folkman J., and Klagsbrun M. Angiogenic factors. Science 235 (1987) 442-447
11. Hanahan D., and Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86 (1996) 353-364
12. Brem S.S., Jensen H.M., and Gullino P.M. Angiogenesis as a marker of preneoplastic lesions of the human breast. Cancer 41 (1978) 239-244
13. Guidi A.J., Abu-Jawdeh G., Berse B., et al. Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in cervical neoplasia. J Natl Cancer Inst 87 (1995) 1237-1245
14. Rak J.W., St Croix B.D., and Kerbel R.S. Consequences of angiogenesis for tumor progression, metastasis and cancer therapy. Anticancer Drugs 6 (1995) 3-18
15. Bergers G., and Benjamin L.E. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3 (2003) 401-410
16. Hicklin D.J., and Ellis L.M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23 (2005) 1011-1027
17. Grunstein J., Roberts W.G., Mathieu-Costello O., Hanahan D., and Johnson R.S. Tumor-derived expression of vascular endothelial growth factor is a critical factor in tumor expansion and vascular function. Cancer Res 59 (1999) 1592-1598
18. Holash J., Wiegand S.J., and Yancopoulos G.D. New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. Oncogene 18 (1999) 5356-5362
19. Forsythe J.A., Jiang B.H., Iyer N.V., et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16 (1996) 4604-4613
20. Hlatky L., Tsionou C., Hahnfeldt P., and Coleman C.N. Mammary fibroblasts may influence breast tumor angiogenesis via hypoxia-induced vascular endothelial growth factor up-regulation and protein expression. Cancer Res 54 (1994) 6083-6086
21. Iliopoulos O., Levy A.P., Jiang C., Kaelin Jr. W.G., and Goldberg M.A. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci USA 93 (1996) 10595-10599
22. Maxwell P.H., Wiesener M.S., Chang G.W., et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399 (1999) 271-275
23. Maxwell P.H., and Ratcliffe P.J. Oxygen sensors and angiogenesis. Semin Cell Dev Biol 13 (2002) 29-37
24. Mandriota S.J., Pyke C., Di Sanza C., Quinodoz P., Pittet B., and Pepper M.S. Hypoxia-inducible angiopoietin-2 expression is mimicked by iodonium compounds and occurs in the rat brain and skin in response to systemic hypoxia and tissue ischemia. Am J Pathol 156 (2000) 2077-2089
25. Gu J., Yamamoto H., Ogawa M., et al. Hypoxia-induced up-regulation of angiopoietin-2 in colorectal cancer. Oncol Rep 15 (2006) 779-783
26. Melillo G., Musso T., Sica A., Taylor L.S., Cox G.W., and Varesio L. A hypoxia-responsive element mediates a novel pathway of activation of the inducible nitric oxide synthase promoter. J Exp Med 182 (1995) 1683-1693
27. Chiarugi V., Magnelli L., Chiarugi A., and Gallo O. Hypoxia induces pivotal tumor angiogenesis control factors including p53, vascular endothelial growth factor and the NFkappaB-dependent inducible nitric oxide synthase and cyclooxygenase-2. J Cancer Res Clin Oncol 125 (1999) 525-528
28. Kuwabara K., Ogawa S., Matsumoto M., et al. Hypoxia-mediated induction of acidic/basic fibroblast growth factor and platelet-derived growth factor in mononuclear phagocytes stimulates growth of hypoxic endothelial cells. Proc Natl Acad Sci USA 92 (1995) 4606-4610
29. Yoshida D., Kim K., Noha M., and Teramoto A. Hypoxia inducible factor 1-alpha regulates of platelet derived growth factor-B in human glioblastoma cells. J Neurooncol 76 (2006) 13-21
30. Graeber T.G., Osmanian C., Jacks T., et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379 (1996) 88-91
31. Hammond E.M., and Giaccia A.J. The role of p53 in hypoxia-induced apoptosis. Biochem Biophys Res Commun 331 (2005) 718-725
32. Jain R.K. Molecular regulation of vessel maturation. Nat Med 9 (2003) 685-693
33. Risau W. Mechanisms of angiogenesis. Nature 386 (1997) 671-674
34. Li B., Sharpe E.E., Maupin A.B., et al. VEGF and PlGF promote adult vasculogenesis by enhancing EPC recruitment and vessel formation at the site of tumor neovascularization. Faseb J 20 (2006) 1495-1497
35. Asahara T., Masuda H., Takahashi T., et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 85 (1999) 221-228
36. Jain R.K., and Duda D.G. Role of bone marrow-derived cells in tumor angiogenesis and treatment. Cancer Cell 3 (2003) 515-516
37. Goon P.K., Lip G.Y., Boos C.J., Stonelake P.S., and Blann A.D. Circulating endothelial cells, endothelial progenitor cells, and endothelial microparticles in cancer. Neoplasia 8 (2006) 79-88
38. De Palma M., Venneri M.A., Roca C., and Naldini L. Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells. Nat Med 9 (2003) 789-795
39. Crosby J.R., Kaminski W.E., Schatteman G., et al. Endothelial cells of hematopoietic origin make a significant contribution to adult blood vessel formation. Circ Res 87 (2000) 728-730
40. Mancuso P., Burlini A., Pruneri G., Goldhirsch A., Martinelli G., and Bertolini F. Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood 97 (2001) 3658-3661
41. Monestiroli S., Mancuso P., Burlini A., et al. Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma. Cancer Res 61 (2001) 4341-4344
42. Less J.R., Skalak T., Sevick E.M., and Jain R.K. Microvascular architecture in a mammary carcinoma: branching patterns and vessel dimensions. Cancer Res 51 (1991) 265-273
43. Konerding M.A., Malkusch W., Klapthor B., et al. Evidence for characteristic vascular patterns in solid tumours: quantitative studies using corrosion casts. Br J Cancer 80 (1999) 724-732
44. Eberhard A., Kahlert S., Goede V., Hemmerlein B., Plate K.H., and Augustin H.G. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res 60 (2000) 1388-1393
45. Sevick E.M., and Jain R.K. Geometric resistance to blood flow in solid tumors perfused ex vivo: effects of tumor size and perfusion pressure. Cancer Res 49 (1989) 3506-3512
46. Tozer G.M., Lewis S., Michalowski A., and Aber V. The relationship between regional variations in blood flow and histology in a transplanted rat fibrosarcoma. Br J Cancer 61 (1990) 250-257
47. Vaupel P., and Hockel M. Blood supply, oxygenation status and metabolic micromilieu of breast cancers: characterization and therapeutic relevance. Int J Oncol 17 (2000) 869-879
48. Boucher Y., Baxter L.T., and Jain R.K. Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy. Cancer Res 50 (1990) 4478-4484
49. Dvorak H.F., Nagy J.A., Dvorak J.T., and Dvorak A. Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am J Pathol 133 (1988) 95-109
50. Hashizume H., Baluk P., Morikawa S., et al. Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 156 (2000) 1363-1380
51. Jain R.K. Transport of molecules across tumor vasculature. Cancer Metastasis Rev 6 (1987) 559-593
52. Baluk P., Morikawa S., Haskell A., Mancuso M., and McDonald D.M. Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors. Am J Pathol 163 (2003) 1801-1815
53. Boucher Y., and Jain R.K. Microvascular pressure is the principal driving force for interstitial hypertension in solid tumors: implications for vascular collapse. Cancer Res 52 (1992) 5110-5114
54. Kobayashi H., Tsuruchi N., Sugihara K., et al. Expression of alpha-smooth muscle actin in benign or malignant ovarian tumors. Gynecol Oncol 48 (1993) 308-313
55. Denekamp J. Vascular attack as a therapeutic strategy for cancer. Cancer Metastasis Rev 9 (1990) 267-282
56. Denekamp J. Review article: angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. Br J Radiol 66 (1993) 181-196
57. Tozer G.M., Prise V.E., Wilson J., et al. Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. Cancer Res 61 (2001) 6413-6422
58. Zwi L.J., Baguley B.C., Gavin J.B., and Wilson W.R. Correlation between immune and vascular activities of xanthenone acetic acid antitumor agents. Oncol Res 6 (1994) 79-85
59. Vaupel P. Tumor microenvironmental physiology and its implications for radiation oncology. Semin Radiat Oncol 14 (2004) 198-206
60. Durand R.E. Keynote address: the influence of microenvironmental factors on the activity of radiation and drugs. Int J Radiat Oncol Biol Phys 20 (1991) 253-258
61. Okunieff P., Hoeckel M., Dunphy E.P., Schlenger K., Knoop C., and Vaupel P. Oxygen tension distributions are sufficient to explain the local response of human breast tumors treated with radiation alone. Int J Radiat Oncol Biol Phys 26 (1993) 631-636
62. Brizel D.M., Dodge R.K., Clough R.W., and Dewhirst M.W. Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. Radiother Oncol 53 (1999) 113-117
63. Nordsmark M., Overgaard M., and Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 41 (1996) 31-39
64. 2-measurements as predictive assay in the treatment of carcinoma of the uterine cervix. Radiother Oncol 53 (1999) 99-104
65. Young S.D., Marshall R.S., and Hill R.P. Hypoxia induces DNA overreplication and enhances metastatic potential of murine tumor cells. Proc Natl Acad Sci USA 85 (1988) 9533-9537
66. Hill R.P. Tumor progression: potential role of unstable genomic changes. Cancer Metastasis Rev 9 (1990) 137-147
67. Giaccia A.J. Hypoxic stress proteins: survival of the fittest. Semin Radiat Oncol 6 (1996) 46-58
68. Brizel D., Scully S., Harrelson J., et al. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 56 (1996) 941-943
69. Gasparini G., Longo R., Fanelli M., and Teicher B.A. Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions. J Clin Oncol 23 (2005) 1295-1311
70. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 (2004) 2335-2342
71. Hurwitz H.I., Fehrenbacher L., Hainsworth J.D., et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 23 (2005) 3502-3508
72. Giantonio B.J., Catalano P.J., Meropol N.J., et al. High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) study E3200. J Clin Oncol (Meeting Abstracts) 23 (2005) 2
73. Laskin J.J., and Sandler A.B. First-line treatment for advanced non-small-cell lung cancer. Oncology (Williston Park) 19 (2005) 1671-1676 1678-1680
74. Ferrara N., and Kerbel R.S. Angiogenesis as a therapeutic target. Nature 438 (2005) 967-974
75. Holash J., Davis S., Papadopoulos N., et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 99 (2002) 11393-11398
76. Hu L., Hofmann J., Holash J., Yancopoulos G.D., Sood A.K., and Jaffe R.B. Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model. Clin Cancer Res 11 (2005) 6966-6971
77. Motzer R.J., Michaelson M.D., Redman B.G., et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24 (2006) 16-24
78. Prenen H., Cools J., Mentens N., et al. Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate. Clin Cancer Res 12 (2006) 2622-2627
79. Ratain M.J., Eisen T., Stadler W.M., et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24 (2006) 2505-2512
80. Heymach J.V. ZD6474-clinical experience to date. Br J Cancer 92 Suppl. 1 (2005) S14-S20
81. Tyagi P. Vatalanib (PTK787/ZK 222584) in combination with FOLFOX4 versus FOLFOX4 alone as first-line treatment for colorectal cancer: preliminary results from the CONFIRM-1 trial. Clin Colorectal Cancer 5 (2005) 24-26
82. Mancuso A., and Sternberg C.N. New treatment approaches in metastatic renal cell carcinoma. Curr Opin Urol 16 (2006) 337-341
83. Lee C.P., Taylor N.J., Attard G., et al. A phase I study of BIBF 1120, an orally active triple angiokinase inhibitor (VEGFR, PDGFR, FGFR) given continuously to patients with advanced solid tumours, incorporating dynamic contrast enhanced magnetic resonance imaging (DCE-MRI). J Clin Oncol (Meeting Abstracts) 24 (2006) 3015
84. Kumar S., and Anderson K.C. Drug insight: thalidomide as a treatment for multiple myeloma. Nat Clin Pract Oncol 2 (2005) 262-270
85. Yang L., Wang J.W., Sun Y., et al. [Randomized phase II trial on escalated doses of Rh-endostatin (YH-16) for advanced non-small cell lung cancer]. Zhonghua Zhong Liu Za Zhi 28 (2006) 138-141
86. de Castro Junior G., Puglisi F., de Azambuja E., El Saghir N.S., and Awada A. Angiogenesis and cancer: a cross-talk between basic science and clinical trials (the "do ut des" paradigm). Crit Rev Oncol/Hematol 59 (2006) 40-50
87. Thorpe P.E. Vascular targeting agents as cancer therapeutics. Clin Cancer Res 10 (2004) 415-427
88. Ching L.M., Cao Z., Kieda C., Zwain S., Jameson M.B., and Baguley B.C. Induction of endothelial cell apoptosis by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer 86 (2002) 1937-1942
89. Hill S.A., Lonergan S.J., Denekamp J., and Chaplin D.J. Vinca alkaloids: anti-vascular effects in a murine tumour. Eur J Cancer 29A (1993) 1320-1324
90. Baguley B.C., Holdaway K.H., Thomsen L.L., Zhuang L., and Zwi L. Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: evidence for a vascular mechanism. Eur J Cancer 27 (1991) 482-487
91. Galbraith S.M., Chaplin D.J., Lee F., et al. Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo. Anticancer Res 21 (2001) 93-102
92. Rustin G.J., Bradley C., Galbraith S., et al. 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study. Br J Cancer 88 (2003) 1160-1167
93. Jameson M.B., Thompson P.I., Baguley B.C., et al. Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent. Br J Cancer 88 (2003) 1844-1850
94. Galbraith S.M., Rustin G.J.S., Lodge M.A., et al. Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging. J Clin Oncol 20 (2002) 3826-3840
95. Tozer G.M., Prise V.E., Wilson J., et al. Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues. Cancer Res 59 (1999) 1626-1634
96. Dowlati A., Robertson K., Cooney M., et al. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 62 (2002) 3408-3416
97. Stevenson J.P., Rosen M., Sun W., et al. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J Clin Oncol 21 (2003) 4428-4438
98. Rustin G.J., Galbraith S.M., Anderson H., et al. Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J Clin Oncol 21 (2003) 2815-2822
99. Galbraith S.M., Maxwell R.J., Lodge M.A., et al. Combretastatin A4 phosphate has tumour anti-vascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol 21 (2003) 2831-2842
100. Anderson H.L., Yap J.T., Miller M.P., Robbins A., Jones T., and Price P.M. Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate. J Clin Oncol 21 (2003) 2823-2830
101. Beerepoot L.V., Radema S.A., Witteveen E.O., et al. Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors. J Clin Oncol 24 (2006) 1491-1498
102. LoRusso P., Gadgeel S., Wozniak A., et al. A phase I dose escalation trial of ZD6126, a novel vascular targeting agent, in patients with cancer refractory to other treatments. Proc AACR-NCI-EORTC (2001) (abstract 36)
103. Gadgeel S., LoRusso P., Wozniak A., and Wheeler C. A dose escalation study of the novel vascular targeting agent ZD6126 in patients with solid tumours. Proc Am Soc Clin Oncol 21 (2002) (abstract 438)
104. DelProposto Z., LoRusso P., Latif Z., et al. MRI evaluation of the effects of the vascular targeting agent ZD6126 on tumor vasculature. Proc Am Soc Clin Oncol 21 (2002) (abstract 440)
105. Hori K., and Saito S. Microvascular mechanisms by which the combretastatin A-4 derivative AC7700 (AVE8062) induces tumour blood flow stasis. Br J Cancer 89 (2003) 1334-1344
106. Sessa C., Lo Russo P., Tolcher A., et al. A pharmacokinetic and DCE-MRI-dynamic phase I study of the antivascular combretastatin analogue AVE8062A administered every 3 weeks. Proc Am Assoc Cancer Res 46 (2005) (abstract 5827)
107. Hill S.A., Tozer G.M., Pettit G.R., and Chaplin D.J. Preclinical evaluation of the antitumour activity of the novel vascular targeting agent Oxi 4503. Anticancer Res 22 (2002) 1453-1458
108. Kirwan I.G., Loadman P.M., Swaine D.J., et al. Comparative preclinical pharmacokinetic and metabolic studies of the combretastatin prodrugs combretastatin A4 phosphate and A1 phosphate. Clin Cancer Res 10 (2004) 1446-1453
109. Hande K.R., Hagey A., Berlin J., et al. The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: results of a phase 1 study. Clin Cancer Res 12 (2006) 2834-2840
110. Fox E., Maris J.M., Widemann B.C., et al. A phase 1 study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 7 days every 21 days in pediatric patients with solid tumors. Clin Cancer Res 12 (2006) 4882-4887
111. Yee K.W., Hagey A., Verstovsek S., et al. Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res 11 (2005) 6615-6624
112. Steel G.G., and Peckham M.J. Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int J Radiat Oncol Biol Phys 5 (1979) 85-91
113. Prise V.E., Honess D.J., Stratford M.R., Wilson J., and Tozer G.M. The vascular response of tumor and normal tissues in the rat to the vascular targeting agent, combretastatin A-4-phosphate, at clinically relevant doses. Int J Oncol 21 (2002) 717-726
114. Siim B.G., Lee A.E., Shalal-Zwain S., Pruijn F.B., McKeage M.J., and Wilson W.R. Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Cancer Chemother Pharmacol 51 (2003) 43-52
115. Horsman M.R., Murata R., Breidahl T., et al. Combretastatins novel vascular targeting drugs for improving anti-cancer therapy. Combretastatins and conventional therapy. Adv Exp Med Biol 476 (2000) 311-323
116. Nelkin B.D., and Ball D.W. Combretastatin A-4 and doxorubicin combination treatment is effective in a preclinical model of human medullary thyroid carcinoma. Oncol Rep 8 (2001) 157-160
117. Li L., Rojiani A.M., and Siemann D.W. Preclinical evaluations of therapies combining the vascular targeting agent combretastatin A-4 disodium phosphate and conventional anticancer therapies in the treatment of Kaposi's sarcoma. Acta Oncol 41 (2002) 91-97
118. Shnyder S.D., Cooper P.A., Pettit G.R., and Lippert III J.W. Combretastatin A-1 phosphate potentiates the antitumour activity of cisplatin in a murine adenocarcinoma model. Anticancer Res 23 (2003) 1619-1623
119. Blakey D.C., Westwood F.R., Walker M., et al. Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. Clin Cancer Res 8 (2002) 1974-1983
120. Goto H., Yano S., Matsumori Y., Ogawa H., Blakey D.C., and Sone S. Sensitization of tumor-associated endothelial cell apoptosis by the novel vascular-targeting agent ZD6126 in combination with cisplatin. Clin Cancer Res 10 (2004) 7671-7676
121. Siemann D.W., and Rojiani A.M. Antitumor efficacy of conventional anticancer drugs is enhanced by the vascular targeting agent ZD6126. Int J Radiat Oncol Biol Phys 54 (2002) 1512-1517
122. Morinaga Y., Suga Y., Ehara S., Harada K., Nihei Y., and Suzuki M. Combination effect of AC-7700, a novel combretastatin A-4 derivative, and cisplatin against murine and human tumors in vivo. Cancer Sci 94 (2003) 200-204
123. Li L., Rojiani A., and Siemann D.W. Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: effects on radiation therapy. Int J Radiat Oncol Biol Phys 42 (1998) 899-903
124. Murata R., Overgaard J., and Horsman M.R. Combretastatin A-4 disodium phosphate: a vascular targeting agent that improves the anti-tumor effects of hyperthermia, radiation, and mild thermoradiotherapy. Int J Radiat Oncol Biol Phys 51 (2001) 1018-1024
125. Murata R., Siemann D.W., Overgaard J., and Horsman M.R. Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors. Radiother Oncol 60 (2001) 155-161
126. Siemann D.W., and Rojiani A.M. Enhancement of radiation therapy by the novel vascular targeting agent ZD6126. Int J Radiat Oncol Biol Phys 53 (2002) 164-171
127. Wilson W.R., Li A.E., Cowan D.S., and Siim B.G. Enhancement of tumor radiation response by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid. Int J Radiat Oncol Biol Phys 42 (1998) 905-908
128. Horsman M.R., and Murata R. Vascular targeting effects of ZD6126 in a C3H mouse mammary carcinoma and the enhancement of radiation response. Int J Radiat Oncol Biol Phys 57 (2003) 1047-1055
129. Horsman M.R., Murata R., and Overgaard J. Improving local tumor control by combining vascular targeting drugs, mild hyperthermia and radiation. Acta Oncol 40 (2001) 497-503
130. Siemann D.W., and Rojiani A.M. The vascular disrupting agent ZD6126 shows increased antitumor efficacy and enhanced radiation response in large, advanced tumors. Int J Radiat Oncol Biol Phys 62 (2005) 846-853
131. Yang J.C., Haworth L., Sherry R.M., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349 (2003) 427-434
132. Huang J., Soffer S.Z., Kim E.S., et al. Vascular remodeling marks tumors that recur during chronic suppression of angiogenesis. Mol Cancer Res 2 (2004) 36-42
133. Kobayashi H., and Lin P.C. Antiangiogenic and radiotherapy for cancer treatment. Histol Histopathol 21 (2006) 1125-1134
134. Rofstad E.K., Mathiesen B., Henriksen K., Kindem K., and Galappathi K. The tumor bed effect: increased metastatic dissemination from hypoxia-induced up-regulation of metastasis-promoting gene products. Cancer Res 65 (2005) 2387-2396
135. Sporn L.A., Rubin P., Marder V.J., and Wagner D.D. Irradiation induces release of von Willebrand protein from endothelial cells in culture. Blood 64 (1984) 567-570
136. Ts'ao C., and Ward W.F. Acute radiation effects on the content and release of plasminogen activator activity in cultured aortic endothelial cells. Radiat Res 101 (1985) 394-401
137. Gorski D.H., Beckett M.A., Jaskowiak N.T., et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 59 (1999) 3374-3378
138. Gupta V.K., Jaskowiak N.T., Beckett M.A., et al. Vascular endothelial growth factor enhances endothelial cell survival and tumor radioresistance. Cancer J 8 (2002) 47-54
139. Abdollahi A., Lipson K.E., Han X., et al. SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro. Cancer Res 63 (2003) 3755-3763
140. Haimovitz-Friedman A., Vlodavsky I., Chaudhuri A., Witte L., and Fuks Z. Autocrine effects of fibroblast growth factor in repair of radiation damage in endothelial cells. Cancer Res 51 (1991) 2552-2558
141. Fuks Z., Persaud R.S., Alfieri A., et al. Basic fibroblast growth factor protects endothelial cells against radiation-induced programmed cell death in vitro and in vivo. Cancer Res 54 (1994) 2582-2590
142. Hast J., Schiffer I.B., Neugebauer B., et al. Angiogenesis and fibroblast proliferation precede formation of recurrent tumors after radiation therapy in nude mice. Anticancer Res 22 (2002) 677-688
143. Tsai J.H., Makonnen S., Feldman M., Sehgal C.M., Maity A., and Lee W.M. Ionizing radiation inhibits tumor neovascularization by inducing ineffective angiogenesis. Cancer Biol Ther 4 (2005) 1395-1400
144. Camphausen K., Moses M.A., Beecken W.-D., Khan M.K., Folkman J., and O'Reilly M.S. Radiation therapy to a primary tumor accelerates metastatic growth in mice. Cancer Res 61 (2001) 2207-2211
145. Hartford A.C., Gohongi T., Fukumura D., and Jain R.K. Irradiation of a primary tumor, unlike surgical removal, enhances angiogenesis suppression at a distal site: potential role of host-tumor interaction. Cancer Res 60 (2000) 2128-2131
146. Rofstad E.K., Galappathi K., and Mathiesen B. Thrombospondin-1 treatment prevents growth of dormant lung micrometastases after surgical resection and curative radiation therapy of the primary tumor in human melanoma xenografts. Int J Radiat Oncol Biol Phys 58 (2004) 493-499
147. Koukourakis M.I., Giatromanolaki A., Sivridis E., et al. Squamous cell head and neck cancer: evidence of angiogenic regeneration during radiotherapy. Anticancer Res 21 (2001) 4301-4309
148. Koukourakis M.I., Giatromanolaki A., Fountzilas G., Sivridis E., Gatter K.C., and Harris A.L. Angiogenesis, thymidine phosphorylase, and resistance of squamous cell head and neck cancer to cytotoxic and radiation therapy. Clin Cancer Res 6 (2000) 381-389
149. Garcia-Barros M., Paris F., Cordon-Cardo C., et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 300 (2003) 1155-1159
150. Kerbel R.S., and Kamen B.A. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 4 (2004) 423-436
151. Schwartzberg L.S., Birch R., Hazelton B., et al. Peripheral blood stem cell mobilization by chemotherapy with and without recombinant human granulocyte colony-stimulating factor. J Hematother 1 (1992) 317-327
152. Browder T., Butterfield C.E., Kraling B.M., et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60 (2000) 1878-1886
153. Bertolini F., Paul S., Mancuso P., et al. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res 63 (2003) 4342-4346
154. Furstenberger G., von Moos R., Lucas R., et al. Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer. Br J Cancer 94 (2006) 524-531
155. Munoz R., Shaked Y., Bertolini F., Emmenegger U., Man S., and Kerbel R.S. Anti-angiogenic treatment of breast cancer using metronomic low-dose chemotherapy. Breast 14 (2005) 466-479
156. Tozer G.M., Kanthou C., and Baguley B.C. Disrupting tumour blood vessels. Nat Rev Cancer 5 (2005) 423-435
157. Wachsberger P., Burd R., and Dicker A.P. Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction. Clin Cancer Res 9 (2003) 1957-1971
158. Murata R., Siemann D.W., Overgaard J., and Horsman M.R. Improved tumor response by combining radiation and the vascular-damaging drug 5,6-dimethylxanthenone-4-acetic acid. Radiat Res 156 (2001) 503-509
159. Wachsberger P.R., Burd R., Marero N., et al. Effect of the tumor vascular-damaging agent, ZD6126, on the radioresponse of U87 glioblastoma. Clin Cancer Res 11 (2005) 835-842
160. Siemann D.W., Mercer E., Lepler S., and Rojiani A.M. Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy. Int J Cancer 99 (2002) 1-6
161. Bilenker J.H., Flaherty K.T., Rosen M., et al. Phase I trial of combretastatin a-4 phosphate with carboplatin. Clin Cancer Res 11 (2005) 1527-1533
162. Pedley R., Hill S., Boxer G., et al. Eradication of colorectal xenografts by combined radioimmunotherapy and combretastatin A-4 3-O-phosphate. Cancer Res 61 (2001) 4716-4722
163. Shaked Y., Ciarrocchi A., Franco M., et al. Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 313 (2006) 1785-1787
164. Siemann D.W., and Shi W. Efficacy of combined antiangiogenic and vascular disrupting agents in treatment of solid tumors. Int J Radiat Oncol Biol Phys 60 (2004) 1233-1240
165. Gabra H. AS1404-202 Study Group Investigators. Phase II study of DMXAA combined with carboplatin and paclitaxel in recurrent ovarian cancer. ASCO Meeting Abstracts 24 (2006) 5032
166. McKeage M. AS1404-201 Study Group Investigators. Phase Ib/II study of DMXAA combined with carboplatin and paclitaxel in non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts 24 (2006) 7102
167. Rustin G.J.S., Nathan P.D., Boxall J., et al. A dose escalation study combining combretastatin A-4 phosphate (CA4P) with carboplatin or paclitaxel in patients with advanced cancer. Clin Cancer Res 11 (2005) 8968
168. Ng Q.S., Carnell D., Milner J., Meer K., Saunders M.I., and Hoskin P.J. Phase Ib trial of combretastatin A4 phosphate (CA4P) in combination with radiotherapy (RT): initial clinical results. J Clin Oncol (Meeting Abstracts) 23 (2005) 3117
169. Nieder C., Wiedenmann N., Andratschke N., and Molls M. Current status of angiogenesis inhibitors combined with radiation therapy. Cancer Treat Rev 32 (2006) 348-364
170. O'Reilly M.S. Radiation combined with antiangiogenic and antivascular agents. Semin Radiat Oncol 16 (2006) 45-50
171. Teicher B.A., Holden S.A., Ara G., et al. Influence of an anti-angiogenic treatment on 9L gliosarcoma: oxygenation and response to cytotoxic therapy. Int J Cancer 61 (1995) 732-737
172. Teicher B.A., Holden S.A., Ara G., Korbut T., and Menon K. Comparison of several antiangiogenic regimens alone and with cytotoxic therapies in the Lewis lung carcinoma. Cancer Chemother Pharmacol 38 (1996) 169-177
173. Murata R., Nishimura Y., and Hiraoka M. An antiangiogenic agent (TNP-470) inhibited reoxygenation during fractionated radiotherapy of murine mammary carcinoma. Int J Radiat Oncol Biol Phys 37 (1997) 1107-1113
174. Lee C.G., Heijn M., di Tomaso E., et al. Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 60 (2000) 5565-5570
175. Ansiaux R., Baudelet C., Jordan B.F., et al. Thalidomide radiosensitizes tumors through early changes in the tumor microenvironment. Clin Cancer Res 11 (2005) 743-750
176. Rofstad E.K., Henriksen K., Galappathi K., and Mathiesen B. Antiangiogenic treatment with thrombospondin-1 enhances primary tumor radiation response and prevents growth of dormant pulmonary micrometastases after curative radiation therapy in human melanoma xenografts. Cancer Res 63 (2003) 4055-4061
177. Fenton B.M., Paoni S.F., Grimwood B.G., and Ding I. Disparate effects of endostatin on tumor vascular perfusion and hypoxia in two murine mammary carcinomas. Int J Radiat Oncol Biol Phys 57 (2003) 1038-1046
178. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307 (2005) 58-62
179. Miller D.W., Vosseler S., Mirancea N., et al. Rapid vessel regression, protease inhibition, and stromal normalization upon short-term vascular endothelial growth factor receptor 2 inhibition in skin carcinoma heterotransplants. Am J Pathol 167 (2005) 1389-1403
180. Vosseler S., Mirancea N., Bohlen P., Mueller M.M., and Fusenig N.E. Angiogenesis inhibition by vascular endothelial growth factor receptor-2 blockade reduces stromal matrix metalloproteinase expression, normalizes stromal tissue, and reverts epithelial tumor phenotype in surface heterotransplants. Cancer Res 65 (2005) 1294-1305
181. Winkler F., Kozin S.V., Tong R.T., et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6 (2004) 553-563
182. Tong R.T., Boucher Y., Kozin S.V., Winkler F., Hicklin D.J., and Jain R.K. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 64 (2004) 3731-3736
183. Lund E.L., Bastholm L., and Kristjansen P.E. Therapeutic synergy of TNP-470 and ionizing radiation: effects on tumor growth, vessel morphology, and angiogenesis in human glioblastoma multiforme xenografts. Clin Cancer Res 6 (2000) 971-978
184. Netti P.A., Hamberg L.M., Babich J.W., et al. Enhancement of fluid filtration across tumor vessels: implication for delivery of macromolecules. PNAS 96 (1999) 3137-3142
185. Huber P.E., Bischof M., Jenne J., et al. Trimodal cancer treatment: beneficial effects of combined antiangiogenesis, radiation, and chemotherapy. Cancer Res 65 (2005) 3643-3655
186. Willett C.G., Chung D., Sahani D., et al. Phase I study of neoadjuvant bevacizumab, 5-fluorouracil, and radiation therapy followed by surgery for patients with primary rectal cancer. J Clin Oncol (Meeting Abstracts) 22 (2004) 3589
187. Crane C.H., Ellis L.M., Abbruzzese J.L., et al. Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer. J Clin Oncol 24 (2006) 1145-1151
188. Siemann D.W., and Keng P.C. In situ radiation response and oxygen enhancement ratio of KHT sarcoma cells in various phases of the cell cycle. Br J Radiol 57 (1984) 823-827
189. Hoang T., Huang S., Armstrong E., Eickhoff J.C., and Harari P.M. Augmentation of radiation response with the vascular targeting agent ZD6126. Int J Radiat Oncol Biol Phys 64 (2006) 1458-1465
190. Bohle A.S., Leuschner I., Kalthoff H., and Henne-Bruns D. Combretastatin A-4 prodrug: a potent inhibitor of malignant hemangioendothelioma cell proliferation. Int J Cancer 87 (2000) 838-843
191. Nabha S.M., Mohammad R.M., Wall N.R., et al. Evaluation of combretastatin A-4 prodrug in a non-Hodgkin's lymphoma xenograft model: preclinical efficacy. Anticancer Drugs 12 (2001) 57-63
192. Mohan R., Banerjee M., Ray A., et al. Antimitotic sulfonamides inhibit microtubule assembly dynamics and cancer cell proliferation. Biochemistry 45 (2006) 5440-5449
193. Flis S., Soltysiak-Pawluczuk D., Jedrych A., Jastrzebski Z., Remiszewska M., and Splawinski J. Antiangiogenic effect of sulindac sulfide could be secondary to induction of apoptosis and cell cycle arrest. Anticancer Res 26 (2006) 3033-3041
194. Yeo E.J., Ryu J.H., Chun Y.S., et al. YC-1 induces S cell cycle arrest and apoptosis by activating checkpoint kinases. Cancer Res 66 (2006) 6345-6352
195. Sartor C.I. Mechanisms of disease: radiosensitization by epidermal growth factor receptor inhibitors. Nat Clin Pract Oncol 1 (2004) 80-87
196. Liu Y., Poon R.T., Li Q., Kok T.W., Lau C., and Fan S.T. Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584. Cancer Res 65 (2005) 3691-3699
197. Huang S.M., Li J., Armstrong E.A., and Harari P.M. Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa). Cancer Res 62 (2002) 4300-4306
198. Zhang Y., Griffith E.C., Sage J., Jacks T., and Liu J.O. Cell cycle inhibition by the anti-angiogenic agent TNP-470 is mediated by p53 and p21WAF1/CIP1. Proc Natl Acad Sci USA 97 (2000) 6427-6432